Hepatoma Research

Scope & Guideline

Pioneering Research for Better Liver Cancer Outcomes

Introduction

Immerse yourself in the scholarly insights of Hepatoma Research with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2394-5079
PublisherOAE PUBLISHING INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2019 to 2024
AbbreviationHEPATOMA RES / Hepatoma Res.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address245 E MAIN ST, ST122, ALHAMBRA, CA 91801

Aims and Scopes

Hepatoma Research is dedicated to advancing the understanding and treatment of liver cancers, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma. The journal emphasizes innovative research methodologies that span clinical, translational, and basic science, aiming to improve patient outcomes and treatment modalities.
  1. Hepatocellular Carcinoma (HCC) Research:
    The journal focuses extensively on various aspects of HCC, including its risk factors, molecular mechanisms, treatment strategies, and outcomes, thereby contributing to a better understanding of this prevalent liver cancer.
  2. Cholangiocarcinoma Studies:
    Cholangiocarcinoma, another critical area of focus, is explored through studies that cover its epidemiology, molecular pathology, and treatment advancements, highlighting the need for improved management strategies.
  3. Innovative Treatment Modalities:
    There is a consistent emphasis on novel treatment approaches, including minimally invasive surgeries, radiation therapies, and the use of immunotherapy and targeted therapies, reflecting the journal's commitment to advancing clinical practice.
  4. Multidisciplinary Approaches:
    The journal promotes multidisciplinary research and treatment approaches, integrating perspectives from surgery, oncology, radiology, and pathology to provide comprehensive care for liver cancer patients.
  5. Patient-Centric Research:
    Hepatoma Research also prioritizes research that addresses patient perspectives, quality of life, and real-world outcomes, fostering a holistic understanding of treatment impacts.
The journal has shown a dynamic evolution in its research focus, with several emerging themes gaining significant attention in recent publications. These trends reflect the ongoing advancements in understanding liver cancer and the pursuit of innovative treatment strategies.
  1. Immunotherapy and Checkpoint Inhibitors:
    Recent publications highlight the growing interest in immunotherapy, particularly immune checkpoint inhibitors, as promising treatment options for HCC, reflecting a shift towards harnessing the immune system in cancer treatment.
  2. Minimally Invasive Surgical Techniques:
    There is an increasing trend in research dedicated to minimally invasive surgical techniques for liver cancer treatment, indicating a broader acceptance and application of these approaches in clinical practice.
  3. Molecular and Genetic Profiling:
    Emerging studies focus on the molecular and genetic profiling of liver cancers, which is crucial for the development of personalized medicine strategies and targeted therapies.
  4. Microbiome and Liver Health:
    Recent articles explore the relationship between the gut microbiome and liver diseases, signaling an emerging interest in how microbial health impacts liver cancer development and progression.
  5. Real-World Data and Patient Outcomes:
    An emphasis on real-world data analysis and patient outcomes has emerged, reflecting a growing interest in understanding the effectiveness and impact of treatments in diverse populations.

Declining or Waning

As the field of liver cancer research evolves, certain themes appear to be diminishing in prominence within the journal's recent publications. These waning scopes may reflect shifts in research priorities or advancements in understanding that render previous approaches less relevant.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in papers focusing on conventional chemotherapy regimens for liver cancer, as newer targeted therapies and immunotherapies gain traction and demonstrate better efficacy.
  2. Basic Science without Clinical Application:
    Research that solely delves into basic science without a clear translational application seems to be less prominent, indicating a shift towards studies that emphasize clinical relevance and applicability in patient care.
  3. Liver Cancer Surveillance Protocols:
    While surveillance remains crucial, the frequency of studies focused on traditional surveillance protocols has decreased, possibly due to increased emphasis on personalized and risk-based screening strategies.

Similar Journals

International Journal of Clinical Oncology

Fostering Excellence in Hematology and Oncology
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

Liver Cancer

Unveiling breakthroughs in hepatology and oncology.
Publisher: KARGERISSN: 2235-1795Frequency: 6 issues/year

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

Surgical Oncology Clinics of North America

Transforming Patient Care through Surgical Innovation
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 1055-3207Frequency: 4 issues/year

Surgical Oncology Clinics of North America, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of surgical oncology and surgery, captivating readers since its inception in 1995. With ISSN 1055-3207 and E-ISSN 1558-5042, this esteemed journal offers a comprehensive platform for the dissemination of cutting-edge research, clinical studies, and expert reviews pertaining to surgical techniques and oncological advancements. The journal currently holds a commendable Q3 ranking in Oncology and a Q2 ranking in Surgery, underpinned by its impressive Scopus rankings that place it in the top 25% of its category in Medicine, particularly in the surgical domain (Rank #137/551). Although it does not operate under an open-access model, the insights shared within its pages are invaluable for researchers, healthcare professionals, and students dedicated to enhancing patient outcomes in surgical oncology. With a commitment to advancing medical knowledge, Surgical Oncology Clinics of North America remains a crucial resource for those pursuing excellence in surgical practices and oncology treatment methodologies.

Clinical and Experimental Hepatology

Advancing Hepatology Through Innovative Research
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 2392-1099Frequency: 4 issues/year

Clinical and Experimental Hepatology is a pivotal journal dedicated to advancing the field of hepatology, providing a platform for researchers, clinicians, and students to disseminate and explore groundbreaking findings. Published by TERMEDIA PUBLISHING HOUSE LTD in Poland, this journal serves as a vital resource for professionals seeking to enhance their knowledge and contributions in the realm of liver diseases and their management. With an impact factor reflective of its growing influence—ranking Q3 in Hepatology for the year 2023 and holding the 49th position out of 82 in Scopus Medicine Hepatology ranks—this publication underscores the significance of innovative research in this specialized domain. While it currently operates through a subscription model rather than open access, it bridges the gap in hepatological literature by featuring a diverse array of scholarly articles, case reports, and reviews from 2015 to 2024. Researchers and health professionals alike will find valuable insights that can enhance clinical practice and inform future studies, solidifying its importance in the hepatology community.

Therapeutic Advances in Medical Oncology

Pioneering open access to vital oncology research.
Publisher: SAGE PUBLICATIONS LTDISSN: 1758-8340Frequency: 1 issue/year

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

Hepatology Communications

Driving discoveries in liver disease and treatment.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: Frequency: 12 issues/year

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.

Oncologie

Elevating oncology research to new heights.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

CURRENT TREATMENT OPTIONS IN ONCOLOGY

Connecting Research to Clinical Excellence in Oncology
Publisher: SPRINGERISSN: 1527-2729Frequency: 12 issues/year

CURRENT TREATMENT OPTIONS IN ONCOLOGY, published by Springer, is a premier academic journal dedicated to disseminating cutting-edge research and advancements in the field of oncology and pharmacology. With a commendable impact factor and ranked in the Q1 category in both oncology and pharmacology for 2023, this journal positions itself as a leading resource for researchers, healthcare professionals, and students alike, offering insightful reviews and original articles that critically evaluate treatment methodologies and clinical practices. Covering a wide scope of topics from early detection to innovative therapies, it fosters the translation of research findings into clinical applications. With its convergence years spanning from 2000 to 2024, CURRENT TREATMENT OPTIONS IN ONCOLOGY continues to be at the forefront of oncological research, providing a platform for scholars to explore the latest therapeutic options and improve patient outcomes. Highly regarded in the academic community, this journal is essential for anyone looking to stay informed about the dynamic landscape of cancer treatment.

Chinese Journal of Cancer Research

Empowering researchers to combat cancer effectively.
Publisher: CHINESE JOURNAL CANCER RESEARCH COISSN: 1000-9604Frequency: 4 issues/year

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.

HEPATOLOGY RESEARCH

Bridging research and practice for improved patient outcomes.
Publisher: WILEYISSN: 1386-6346Frequency: 12 issues/year

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.